HOME >> MEDICINE >> NEWS
Database of cancer records now available for research

Data on more than 22,000 cancer cases are now available for research by bona fide clinical and medical researchers. This repository is the first major output of the Clinical e-Science Framework (CLEF), an e-Science project funded by the Medical Research Council (MRC). Sophisticated security systems, also developed by CLEF, ensure secure and ethical access to the databank. Dr Catalina Hallett will demonstrate the query of the new database at the e-Science All Hands meeting in Nottingham on 20 September.

Patient records contain a wealth of information that could be very useful to medical research. To make this information accessible to researchers, however, it must be extracted from what is often written text and presented in such a way that it can be compared with data from scientific and other databases. CLEF has developed techniques to capture relevant information from text automatically and enter it into a database. The project has also implemented stringent access control, authentication and secure transmission protocols using sophisticated encryption standards to protect against accidental disclosures.

Professor Alan Rector, CLEF's director, said: "The CLEF repository is optimised to treat electronic healthcare records as an interactive knowledge source for academic researchers and clinicians to help them access the latest medical information. Once fully deployed, it will lead to previously unthinkable, rapid advances in healthcare research by enabling researchers to analyse data stored in a wide range of geographically-spread databases, on-line."

Professor David Ingram's team at University College, London built the repository using a new method for importing and structuring data so that users can do population queries over longitudinal data sets. The CLEF repository supports the large-scale analysis of patient records in a Grid environment. It can handle complex queries, whilst retaining the critical semantic, structural and medic
'"/>

Contact: Judy Redfearn
judy.redfearn@epsrc.ac.uk
44-7-768-356-309
Engineering and Physical Sciences Research Council
21-Sep-2005


Page: 1 2

Related medicine news :

1. Wiley acquires HEED, the worlds leading Health Economic Evaluations Database
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Survival differences by race most apparent in advanced stages of breast cancer
4. Stomach cancer rate set to fall further 25 percent over next decade
5. MRI finds breast cancer before it becomes dangerous
6. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
7. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
8. Pathway links inflammation, angiogenesis and breast cancer
9. Using MRI for diagnosis could help prevent breast cancer progression
10. Electric fields have potential as a cancer treatment
11. Shining light on pancreatic cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Database cancer records now available for research

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
(Date:5/21/2013)... Schaumburg, IL (PRWEB) May 21, 2013 ... administration for large, medium, and small organizations, will be ... featuring an experts team from Findley Davies. The presentation ... is up-to-date and in compliance with new Health Care ... ideas to engage employees. , “Benefit Express regularly ...
(Date:5/21/2013)... May 21, 2013 Dr. Francine Kaufman , ... she used with her patients in the 1980s: It weighed several ... For the most part, it could only be used in the ... years since then, and the advantages are greater as well. The ... outside of the body, often on a belt or a pocket. ...
(Date:5/21/2013)... 21, 2013 A plastic surgery ... for plastic surgery SEO services following an Internet ... to name the “Best Plastic Surgery SEO Services”. ... outcome was predictable. Well-known in the plastic surgery ... patients than any other selection based on superior ...
Breaking Medicine News(10 mins):Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2
(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013  Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... study is to offer synopsis of the ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: